title: Response to: 'Baseline differences in SAVOR trial'-- prespecified vs. post hoc analysis--a potential source of bias.
authors.forename: I
authors.initials: I
authors.lastname: Raz
authors.affiliation: Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Cahn
authors.affiliation: Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Mosenzon
authors.affiliation: Heart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Scirica
authors.affiliation: Heart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Bhatt
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000009:adverse effects*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D006801:Humans
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D000218:Adamantane